Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02452970
Title RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors EpicentRx, Inc.
Indications

biliary tract cancer

cholangiocarcinoma

Therapies

RRx-001

Cisplatin + Gemcitabine

Age Groups: adult
Covered Countries USA


No variant requirements are available.